Kritika Rehani

  DelveInsight launched a report titled,  “ Infliximab Biosimilar Insights, 2020 ,”  which provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. The report covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.  Geography Covered ·         Global coverage View full report:  https://www.delveinsight.com/report-store/infliximab-biosimilars-insight Infliximab Overview Infliximab , a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. Infliximab is produced

Diffuse Intrinsic Pontine Gliomas (DIPG)  (also known as Pontine Glioma or Brainstem Glioma) are  highly aggressive  and difficult to treat  brain tumors found at the base of the brain . They are glial tumors that arise from the brain's glial tissue (tissue made up of cells that help support and protect the brain's neurons). These tumors are found in an area of the brainstem (the lowest, stem-like part of the brain) called the pons, which controls many of the body’s most vital functions, such as breathing, blood pressure, and heart rate. DelveInsight's " Diffuse Intrinsic Pontine Glioma (DIPG) Market Report 2030 " delivers an in-depth understanding of the Diffuse Intrinsic Pontine Glioma (DIPG) , historical and forecasted epidemiology as well as the Diffuse Intrinsic Pontine Glioma (DIPG) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Diffuse Intrinsic Pontine Glioma (DIPG) Disease Understanding and Treatment

Hepatitis delta, also known as hepatitis D or HDV is a liver infection caused by the hepatitis delta virus that results in the most severe form of viral hepatitis known to humans. However, only those already infected with hepatitis B can acquire hepatitis delta, as it is dependent on the hepatitis B virus to reproduce. The HDV infection is of two types: superinfection and co-infection. Super infections occur when a person with chronic hepatitis B becomes infected with hepatitis delta. These types of infections are more common and have a 70‒90% chance of resulting in a chronic infection of both hepatitis B and delta. Co-infections occur when a person gets infected with hepatitis B and delta at the same time, and have a <5% chance of resulting in chronic infections. DelveInsight's " Chronic Hepatitis Delta Virus (HDV) Infection Market Report 2030 "  delivers an in-depth understanding of the Chronic Hepatitis Delta Virus (HDV) Infection, historical and forecasted epidemio